CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 21 enrolled
Drug / intervention
Pegylated interferon alfa-2a + Ribavirindrug
Likely dose
Pegylated interferon alfa-2a 180 mcg subcutaneous once weekly for 24 weeks; Ribavirin 1000-1200 mg daily (divided twice daily) for 12-24 weeksAI-extracted
Key inclusion· 3
  • ✓Newly acquired HCV infection of 6 months or less duration
  • ✓Detectable HCV RNA at study entry
  • ✓HIV infection, any CD4 count
Key exclusion· 3
  • ✕Pregnant or intent to become pregnant within 24 weeks of study completion
  • ✕Uncontrolled depression
  • ✕Other serious liver disease

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00845676
NCT00845676Phase 4Completed
CompareCT.gov

Treatment of Acute Hepatitis C Virus in HIV Co-Infection

University of California, San Francisco·interventional·Posted Feb 18, 2009·Updated May 18, 2020

In Brief

A Phase 4 clinical trial evaluating Pegylated interferon alfa-2a + Ribavirin for Hepatitis C and 2 related conditions. Completed, enrolled 21 participants across 1 site.

Detailed Summary

This study is designed to test the hypothesis that treatment of hepatitis C virus (HCV) infection during the first 6 months after acquiring HCV among people who already have pre-existing HIV infection will result in improved responses to HCV therapy with a shorter duration of infection.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatitis C, Human Immunodeficiency Virus, HIV Infections
CountriesUnited States
CollaboratorsCalifornia HIV/AIDS Research Program

Timeline

Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 18, 2009
Enrollment StartMar 1, 2008
Primary CompletionDec 1, 2010
Study CompletionDec 1, 2013
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 17.4 years ago

Interventions

Pegylated interferon alfa-2a + Ribavirindrug

Pegylated interferon alfa-2a 180 mcg subcutaneous injection once weekly for 24 weeks Ribavirin 1000-1200mg daily, dosed according to body weight and divided twice daily, for 12-24 weeks